

# Role of Protein Kinase C $\zeta$ and Its Adaptor Protein p62 in Voltage-Gated Potassium Channel Modulation in Pulmonary Arteries

Laura Moreno, Giovanna Frazziano, Angel Cogolludo, Laura Cobeño, Juan Tamargo, and Francisco Perez-Vizcaino

Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain

Received April 12, 2007; accepted August 15, 2007

## ABSTRACT

Voltage-gated potassium ( $K_V$ ) channels play an essential role in regulating pulmonary artery function, and they underpin the phenomenon of hypoxic pulmonary vasoconstriction. Pulmonary hypertension is characterized by inappropriate vasoconstriction, vascular remodeling, and dysfunctional  $K_V$  channels. In the current study, we aimed to elucidate the role of PKC $\zeta$  and its adaptor protein p62 in the modulation of  $K_V$  channels. We report that the thromboxane  $A_2$  analog 9,11-dideoxy-11 $\alpha$ ,9 $\alpha$ -epoxymethano-prostaglandin  $F_{2\alpha}$  methyl acetate (U46619) inhibited  $K_V$  currents in isolated mice pulmonary artery myocytes and the  $K_V$  current carried by human cloned  $K_V1.5$  channels expressed in Ltk<sup>-</sup> cells. Using protein kinase C (PKC) $\zeta^{-/-}$  and

p62<sup>-/-</sup> mice, we demonstrate that these two proteins are involved in the  $K_V$  channel inhibition. PKC $\zeta$  coimmunoprecipitated with  $K_V1.5$ , and this interaction was markedly reduced in p62<sup>-/-</sup> mice. Pulmonary arteries from PKC $\zeta^{-/-}$  mice also showed a diminished  $[Ca^{2+}]_i$  and contractile response, whereas genetic inactivation of p62<sup>-/-</sup> resulted in an absent  $[Ca^{2+}]_i$  response, but it preserved contractile response to U46619. These data demonstrate that PKC $\zeta$  and its adaptor protein p62 play a key role in the modulation of  $K_V$  channel function in pulmonary arteries. These observations identify PKC $\zeta$  and/or p62 as potential therapeutic targets for the treatment of pulmonary hypertension.

Voltage-gated potassium ( $K_V$ ) channels play an essential role in regulating vascular smooth muscle function. They make a substantial contribution to whole-cell  $K^+$  conductance and resting membrane potential in pulmonary artery smooth muscle cells (PASMCs), and its inhibition causes membrane depolarization, activation of L-type  $Ca^{2+}$  channels ( $Ca_L$ ), increases in  $[Ca^{2+}]_i$ , and vasoconstriction (Barnes and Liu, 1995; Archer et al., 1998; Yuan et al., 1998b). These channels are common targets of pulmonary vasoconstrictor stimuli such as hypoxia, thromboxane  $A_2$  (TXA $_2$ ), 5-hydroxytryptamine, endothelin-1 or angiotensin-II (Archer et al., 1998; Shimoda et al., 2001; Cogolludo et al., 2003, 2006). In

addition, decreased expression or function of  $K_V$  channels in PASMCs has been involved in the pathogenesis of pulmonary arterial hypertension (PH) (Weir et al., 1996; Yuan et al., 1998a; Pozeg et al., 2003). From the variety of  $K_V$  channels expressed in PASMC (Platoshyn et al., 2006), special interest has been paid to  $K_V1.5$ , because decreased expression or activity and mutations of  $K_V1.5$  occur in human (Yuan et al., 1998a; Remillard et al., 2007) and experimental (Archer et al., 1998; Pozeg et al., 2003) idiopathic and hypoxic PH, and in vivo gene transfer of  $K_V1.5$  reduces PH (Pozeg et al., 2003).

TXA $_2$  is a prostanoid synthesized by cyclooxygenase with potent vasoconstrictor, mitogenic, and platelet aggregant properties via activation of thromboxane-endoperoxide (TP) receptors (Halushka et al., 1989). The vasoconstrictor effects of TXA $_2$  are particularly pronounced in the pulmonary vascular bed, where it participates in the control of vessel tone under physiological and pathological situations, including PH. We have previously reported that in intact PAs and freshly isolated PASMCs, TXA $_2$ , via activation of TP receptors, inhibits  $K_V$  channels, leading to membrane depolariza-

This study was supported by grants from Ministerio de Educación y Ciencia (Comisión Interministerial de Ciencia y Tecnología: SAF2005-03770, AGL2004-06685, SAF2005-04609; Formación de Profesorado Universitario: to L.M. and G.F., Formación de Personal Investigador: to L.C.) and Fundación Mutua Madrileña.

L.M. and G.F. contributed equally to this work.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.107.037002.

**ABBREVIATIONS:**  $K_V$ , voltage-gated  $K^+$ ; PASMC, pulmonary artery smooth muscle cell;  $Ca_L$ , voltage-dependent L-type  $Ca^{2+}$  channel; TXA $_2$ , thromboxane  $A_2$ ; PH, pulmonary hypertension; TP, thromboxane-endoperoxide; PKC, protein kinase C; PA, pulmonary artery; IP, inhibitory peptide; aPKC, atypical PKC; PSS, physiological salt solution; h, human; U46619, 9,11-dideoxy-11 $\alpha$ ,9 $\alpha$ -epoxymethano-prostaglandin  $F_{2\alpha}$ ; DPO-1, [1S-1 $\alpha$ ,2 $\alpha$ ,5 $\beta$ ]-[5-methyl-2-(1-methylethyl) cyclohexyl] diphenyl phosphine oxide.

tion, activation of L-type  $\text{Ca}^{2+}$  channels, and vasoconstriction. Furthermore, using a protein kinase C (PKC) $\zeta$  pseudosubstrate inhibitory peptide (PKC $\zeta$ -PI), we provided evidence for the role of this kinase as a link between TP receptor activation and  $\text{K}_V$  channel inhibition (Cogolludo et al., 2003, 2005). PKC $\zeta$  (together with PKC $\lambda/\iota$ ) belongs to the atypical PKC (aPKC) subclass. Both aPKCs play key roles in different signaling pathways regulating cell growth, survival, and differentiation (Moscat and Diaz-Meco, 2000). The aPKCs share with other members of their family a conserved catalytic domain, but they display a clearly distinct regulatory region because they have been shown to be independent of  $\text{Ca}^{2+}$ , diacylglycerol, and phorbol esters, all of which are potent activators of other PKC isoforms. PKC $\zeta$  is activated by phosphatidylinositols, arachidonic acid, and other lipids (Hirai and Chida, 2003) as well as by a variety of mediators, including insulin (Liu et al., 2006), thromboxane  $\text{A}_2$  (Shizukuda and Buttrick, 2002; Cogolludo et al., 2003, 2005), angiotensin II (Gayral et al., 2006; Godeny and Sayeski, 2006), or proinflammatory cytokines (Frey et al., 2006).

The mechanism underlying the activation of aPKCs responsible for its diverse physiological functions remains unclear, but several groups have identified a number of aPKC-interacting proteins, including p62 (also called ZIP1 or sequestosome 1), Par-4, Par-6, and MEK5 (Moscat and Diaz-Meco, 2000). It is noteworthy that nerve growth factor and catecholamines have been reported to increase the expression of p62, enabling the formation of the PKC $\zeta$ -p62- $\text{K}_V\beta$  complex, which results in a hyperpolarizing shift in the  $\text{K}_V$  current activation curve (Gong et al., 1999; Kim et al., 2004, 2005).

The role of PKC on pulmonary vasoconstriction has been widely reported (Ward et al., 2004); however, many of these studies have been conducted with PKC modulators of dubious selectivity, thereby limiting their conclusions. Molecular biology and genetic approaches and the currently available isoform-selective PKC inhibitors have made possible the elucidation of the involvement of specific PKC isoforms in cellular processes (such as vascular contractility) (Salamanca and Khalil, 2005). However, recent evidence suggests that some considered isoform-specific PKC inhibitors, such as myristoylated PKC $\zeta$  pseudosubstrate peptide, may exert other effects unrelated to inhibition of PKC; thus, they should be used with caution (Krotova et al., 2006).

Therefore, in the present study, we aimed to further characterize the signaling pathway modulating  $\text{K}_V$  currents in PAs. Using PKC $\zeta^{-/-}$  and p62 $^{-/-}$  mice, we provide evidence for the interaction of PKC $\zeta$  with  $\text{K}_V$  channels, which further support the role of this interaction in  $\text{TXA}_2$ -induced effects. In addition, we hypothesized that the PKC $\zeta$ - $\text{K}_V$ -L-type  $\text{Ca}^{2+}$  channels pathway might involve other proteins such as p62. This possibility was tested by analyzing the modulation of  $\text{K}_V$  channels in wild-type and p62 homozygous null mice.

## Materials and Methods

All experiments were carried out in accordance with the European Animals Act 1986 (Scientific Procedures), and they were approved by our institutional review board.

**Animals.** Lungs from PKC $\zeta^{-/-}$  (mixed C57BL/6 and SV129J background), p62 $^{-/-}$  (C57BL/6), and corresponding wild-type mice (6–8 weeks old; either sex) were generously supplied by Drs. J.

Moscat and M. T. Diaz-Meco (both from the Genome Research Institute, University of Cincinnati, Cincinnati, OH). These mice were generated as described previously (Leitges et al., 2001; Duran et al., 2004). PAs from male Wistar rats (250–300 g) were also used in these experiments.

**Tissue Preparation and Cell Isolation.** Second-order branches of the PA (internal diameter,  $\leq 0.5$  mm) isolated from mice were dissected into a nominally calcium-free physiological salt solution (PSS) of the following composition: 130 mM NaCl, 5 mM KCl, 1.2 mM  $\text{MgCl}_2$ , 10 mM glucose, and 10 mM HEPES, pH 7.3, with NaOH. Endothelium denuded PAs were cut into small segments ( $2 \times 2$  mm), and cells were isolated in  $\text{Ca}^{2+}$ -free PSS containing 1 mg/ml papain, 0.8 mg/ml dithiothreitol, and 0.7 mg/ml albumin. Cells were stored in  $\text{Ca}^{2+}$ -free PSS (4°C) and used within 8 h of isolation.

**Electrophysiological Studies.** Membrane currents were measured using the whole-cell configuration of the patch-clamp technique (Cogolludo et al., 2003) normalized for cell capacitance and expressed in picoamperes per picrofarad. Membrane potential ( $E_m$ ) was measured under current-clamp configuration.  $\text{K}_V$  currents were recorded under essentially  $\text{Ca}^{2+}$ -free conditions using an external  $\text{Ca}^{2+}$ -free PSS and a  $\text{Ca}^{2+}$ -free pipette (internal) solution (see Solutions and Chemicals). Ltk $^-$  cells stably expressing h $\text{K}_V1.5$  channels (Valenzuela et al., 1995) were superfused with PSS containing 1 mM  $\text{CaCl}_2$ . Currents were evoked after the application of 200-ms depolarizing pulses from  $-60$  mV to test potentials from  $-60$  to  $+40$  mV in 10-mV increments. All experiments were performed at room temperature (22–24°C).

**$[\text{Ca}^{2+}]_i$  Recording.** PA rings were incubated for 80 min at room temperature in Krebs' solution containing the fluorescent dye fura-2 acetoxymethyl ester ( $5 \times 10^{-6}$  M) and 0.05% cremophor EL, and then they were mounted in a fluorimeter (model CAF 110; Jasco, Tokyo, Japan). PA rings were alternatively illuminated (128 Hz) with two excitation wavelengths (340 and 380 nm), and the emitted fluorescence was filtered at 505 nm (Pérez-Vizcaino et al., 1999). The ratio of emitted fluorescence ( $F_{340}/F_{380}$ ) obtained at the two excitation wavelengths was used as an indicator of  $[\text{Ca}^{2+}]_i$ . Arteries were stimulated with 30 and 300 nM U46619, added in a cumulative manner. In preliminary experiments in wild-type mice, these concentrations produced  $\sim 60$  and  $\sim 80\%$  of the maximal response, respectively. The  $[\text{Ca}^{2+}]_i$  signal in each vessel was calibrated according to the Grynkiewicz equation by sequential addition of 15  $\mu\text{M}$  ionomycin and 10 mM EGTA at the end of the experiment.

**Coimmunoprecipitation and Western Blot Analysis.** Mice lungs were rapidly frozen in liquid nitrogen. In some experiments, rat PA were placed in warm Krebs' solution and then in the absence or presence of 1  $\mu\text{M}$  U46619 for 30 s and then rapidly frozen. Frozen tissues were homogenized in a glass potter in 200  $\mu\text{l}$  of a buffer of the following composition: 10 mM HEPES, pH 8, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 6  $\mu\text{M}$  aprotinin, 9  $\mu\text{M}$  leupeptin, 11  $\mu\text{M}$  *N* $\alpha$ -p-tosyl-L-lysine chloromethyl ketone, 5 mM NaF, 10 mM  $\text{Na}_2\text{MoO}_4$ , 1 mM  $\text{NaVO}_4$ , 0.5 mM phenylmethanesulfonyl fluoride, and 10 mM okadaic acid. Homogenates were centrifuged at 13,000g for 5 min at 4°C, and the supernatant fraction was collected. For immunoprecipitation, 60  $\mu\text{g}$  of protein was incubated for 2 h with anti-PKC $\zeta$  or anti- $\text{K}_V1.5$  antibody at 4°C, followed by the addition of protein A/G beads and further incubation overnight. These immune complexes or 20  $\mu\text{g}$  of the homogenates from mice lungs or rat PA were separated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane for Western blotting as described previously (Cogolludo et al., 2003). Membranes were probed for  $\text{K}_V1.5$ -, PKC $\zeta$ -, and p62-like immunoreactivity.

**Solutions and Chemicals.** For the single cell electrophysiological studies, the composition of the  $\text{Ca}^{2+}$ -free bath solution (external  $\text{Ca}^{2+}$ -free PSS) was as follows: 130 mM NaCl, 5 mM KCl, 1.2 mM  $\text{MgCl}_2$ , 10 mM glucose, and 10 mM HEPES, buffered to pH 7.3 with NaOH. The  $\text{Ca}^{2+}$ -free pipette (internal) solution contained 110 mM KCl, 1.2 mM  $\text{MgCl}_2$ , 5 mM  $\text{Na}_2\text{ATP}$ , 10 mM HEPES, and 10 mM EGTA, pH adjusted to 7.3 with KOH. The Krebs' solution used for

tissue bath experiments included 118 mM NaCl, 4.75 mM KCl, 25 mM NaHCO $_3$ , 1.2 mM MgSO $_4$ , 2.0 mM CaCl $_2$ , 1.2 mM KH $_2$ PO $_4$ , and 11 mM glucose. This solution was gassed with a 95% O $_2$ , 5% CO $_2$  mixture at 37°C. U46619 was obtained from Sigma Chemical Co. (Tres Cantos, Spain). [1S-1 $\alpha$ ,2 $\alpha$ ,5 $\beta$ ]-[5-Methyl-2-(1-methylethyl) cyclohexyl] diphenyl phosphine oxide (DPO-1) was from Tocris Cookson Inc. (Bristol, UK), secondary horseradish peroxidase-conjugated antibodies and fura-2 acetoxymethyl ester were from Calbiochem (Barcelona, Spain), rabbit anti-K $_V$ 1.5 was from Alomone Labs (Jerusalem, Israel), goat anti-PKC $\zeta$  was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and guinea pig anti-p62 was from Progen (Heidelberg, Germany).


**Statistical Analysis.** Data are expressed as means  $\pm$  S.E.M.;  $n$  indicates the number of arteries or cells tested. All experiments were conducted in arteries or cells from at least four different animals. Statistical analysis was performed using Student's  $t$  test for paired or unpaired observations. Differences were considered statistically significant when  $p$  was less than 0.05.

## Results

**Role of PKC $\zeta$  in K $_V$  Current Inhibition Induced by TXA $_2$ .** A family of K $_V$  currents [ $I_{K(V)}$ ] were obtained in mice

PASMCs when eliciting depolarizing steps from  $-60$  to  $+40$  mV (Fig. 1, A and B) from a holding potential of  $-60$  mV. The magnitude of the currents, the threshold voltage for activation, and the current-voltage relationship (Fig. 1, C and D) was similar in PASMCs from wild-type and PKC $\zeta^{-/-}$  mice (e.g., current density at  $+40$  mV was  $9.1 \pm 1.9$  and  $8.7 \pm 0.8$  pA/pF, respectively). Current inactivation was also similar in both strains (i.e., at 200 ms, the current decayed by  $11.5 \pm 3$  and  $12.1 \pm 3.8\%$ , respectively). Currents were recorded before (control) and after addition of the TXA $_2$  analog U46619. U46619 (100 nM) caused a significant inhibition of K $_V$  currents in the whole range of channel activation in PASMCs from wild-type mice (Fig. 1A). The degree of current inactivation at  $+40$  mV was increased by U46619 (i.e., at 200 ms, the current decayed by  $25.6 \pm 4.8\%$ ;  $p < 0.05$ ). In addition, U46619 induced membrane depolarization in wild-type PASMCs (Fig. 1E). However, U46619 had no effect on either K $_V$  currents or membrane potentials in PASMC from PKC $\zeta^{-/-}$  mice (Fig. 1, B, D, and F).

**Role of PKC $\zeta$  in [Ca $^{2+}$ ] $_i$  Increase and Contraction Induced by TXA $_2$ .** Changes in [Ca $^{2+}$ ] $_i$  and contraction in-




**Fig. 1.** TP receptor activation leads to K $_V$  current inhibition and depolarization in PASMCs from PKC $\zeta^{+/+}$  (A, C, and E) but not from PKC $\zeta^{-/-}$  (B, D, and F) mice. A and B, current traces for 200-ms depolarization pulses from  $-60$  to  $+40$  mV (in 10-mV increments) from a holding potential of  $-60$  mV before (control) and after application of the TXA $_2$  analog U46619 (100 nM). C and D, current-voltage relationship measured at the end of the 200-ms pulse (means  $\pm$  S.E.M. of five cells). E and F, effects of 100 nM U46619 on membrane potential recorded under current clamp conditions. \*,  $p < 0.05$  and \*\*,  $p < 0.01$ , respectively, versus control (paired Student's  $t$  test).

duced by U46619 were simultaneously analyzed in fura-2-loaded PAs from wild-type and from  $\text{PKC}\zeta^{-/-}$  mice. Basal levels of  $[\text{Ca}^{2+}]_i$  in  $\text{PKC}\zeta^{-/-}$  ( $203 \pm 40$  nM;  $n = 6$ ) were not significantly different from those in wild-type mice ( $160 \pm 40$  nM;  $n = 6$ ). Stimulation of endothelium-denuded PA rings with 30 and 300 nM U46619 induced a sustained elevation in  $[\text{Ca}^{2+}]_i$  and a contractile response in PAs from wild-type and  $\text{PKC}\zeta^{-/-}$  animals (Fig. 2, A and B). However, the increase in  $[\text{Ca}^{2+}]_i$  (Fig. 2C) and the contractile response (Fig. 2D) was significantly reduced in  $\text{PKC}\zeta^{-/-}$  mice compared with wild-type mice.

**Role of p62 in  $\text{K}_V$  Current Inhibition,  $[\text{Ca}^{2+}]_i$  Increase, and Contraction.** To analyze the functional role of p62 and the  $\text{PKC}\zeta$ -p62- $\text{K}_V1.5$  interaction, we analyzed the effects of 100 nM U46619 on  $\text{K}_V$  currents in  $\text{p62}^{-/-}$  and the

corresponding wild-type mice. The magnitude of the currents, the threshold voltage for activation, the current-voltage relationship, and the current inactivation (Fig. 3, C and D) were similar in PASMCS from wild-type and  $\text{p62}^{-/-}$  mice (e.g., current density at +40 mV was  $10.9 \pm 1.3$  and  $11.6 \pm 1.7$  pA/pF, respectively; and at 200 ms, current decayed by  $12.7 \pm 2.8$  and  $14.3 \pm 2.9\%$ , respectively). As expected, U46619 caused a significant inhibition in the whole range of channel activation and depolarized the membrane in PASMCS from wild-type mice (Fig. 3, A, C, and E). Current inactivation at +40 mV was also increased by U46619 (i.e., at 200 ms, the current decayed by  $21.7 \pm 2.9\%$ ;  $p < 0.05$ ). However, the  $\text{TXA}_2$  analog had no effect on  $\text{K}_V$  currents in PASMCS from  $\text{p62}^{-/-}$  mice (Fig. 3, B, D, and E).

Basal levels of  $[\text{Ca}^{2+}]_i$  in  $\text{p62}^{-/-}$  ( $184 \pm 35$  nM;  $n = 5$ ) were



**Fig. 2.** PA from  $\text{PKC}\zeta^{-/-}$  mice show reduced  $[\text{Ca}^{2+}]_i$  and contractile responses induced by TP receptor activation. A and B, simultaneous recordings of  $[\text{Ca}^{2+}]_i$  (top trace) and force (bottom trace) in PAs from  $\text{PKC}\zeta^{+/+}$  and  $\text{PKC}\zeta^{-/-}$ , respectively, stimulated by 30 and 300 nM U46619. The averaged values (means  $\pm$  S.E.M. of five to seven PAs) of U46619-induced increase in  $[\text{Ca}^{2+}]_i$  and force are shown in C and D, respectively. \*,  $p < 0.05$  versus  $\text{PKC}\zeta^{+/+}$  (unpaired Student's  $t$  test).




not significantly different from those in wild-type mice ( $170 \pm 45$  nM;  $n = 6$ ). We found that genetic inactivation of p62 abolished the increase in  $[Ca^{2+}]_i$  induced by U46619 (Fig. 4, B and C). However, the contractile response induced by the two concentrations of U46619 tested was remarkably similar in p62 $^{-/-}$  and wild-type mice (Fig. 4D).

**Role of K $_V$ 1.5 Channels in TXA $_2$ -Induced Effects.** K $_V$ 1.5 channels have been reported to be major contributors of K $_V$  currents in PSMCs in several animal species. Figure 5A shows hK $_V$ 1.5 current traces recorded in Ltk $^{-}$  cells stably expressing hK $_V$ 1.5 channels. U46619 (100 nM) significantly inhibited hK $_V$ 1.5 currents. This inhibitory effect was only observed at the end of the depolarizing pulse; e.g., currents were almost unaffected at the peak ( $4.6 \pm 2.4\%$  decrease; not significant), but they were reduced by  $17.8 \pm 4.2\%$  after 200 ms ( $n = 4$ ;  $p < 0.05$ ). In rat PSMCs, U46619 also inhibited K $_V$  currents (Fig. 5B) as described previously (Cogolludo et al., 2003). The K $_V$ 1.5 channel blocker DPO-1 (Lagrutta et al., 2006) inhibited K $_V$  currents in rat PSMCs. In the presence of DPO-1, U46619 produced no further inhibitory effects (Fig. 5B). Therefore, we analyzed a possible interaction between

PKC $\zeta$ , K $_V$ 1.5 channels and p62. Rat pulmonary arteries were incubated for 30 s in the absence (control) or presence of U46619. Homogenates were immunoprecipitated with anti-PKC $\zeta$  or anti-K $_V$ 1.5 antibodies, and the content of K $_V$ 1.5, PKC $\zeta$ , or p62 in the immunoprecipitates was analyzed via Western blot. Figure 5C shows that in immunoprecipitates of K $_V$ 1.5 both PKC $\zeta$  and p62 were present. The K $_V$ 1.5-PKC $\zeta$  and the K $_V$ 1.5-p62 association were  $135 \pm 13\%$  ( $n = 8$ ;  $p = 0.06$ , not significant) and  $163 \pm 31\%$  ( $n = 7$ ;  $p < 0.05$ ), respectively, in U46619-treated versus untreated arteries. The K $_V$ 1.5-PKC $\zeta$  interaction was also observed in immunoprecipitates of PKC $\zeta$  immunoblotted with the anti-K $_V$ 1.5 antibody (data not shown).

**Interaction of PKC $\zeta$  with K $_V$  Channels: Role of p62.** To determine the potential role of the PKC $\zeta$  scaffold protein p62, the PKC $\zeta$ -K $_V$ 1.5 interaction was analyzed by coimmunoprecipitation in lungs from wild-type and p62 $^{-/-}$  mice. Genetic inactivation of p62 in mice did not modify the expression levels of either PKC $\zeta$  or K $_V$ 1.5 channels in PSMCs (Fig. 6A). In immunoprecipitates of PKC $\zeta$  from wild-type mice immunoblotted with the anti-K $_V$ 1.5 antibody, a band of approx. 80 kDa was



**Fig. 3.** TP receptor activation leads to K $_V$  current inhibition and depolarization in PSMCs from wild-type (A, C, and E) but not from p62 $^{-/-}$  (B, D, and F) mice. A and B, current traces for 200-ms depolarization pulses from  $-60$  to  $+40$  mV (in 10-mV increments) from a holding potential of  $-60$  mV before (control) and after application of the TXA $_2$  analog U46619 (100 nM). C and D, current-voltage relationship measured at the end of the 200-ms pulse (means  $\pm$  S.E.M. of five to six cells). E and F, effects of U46619 on membrane potential recorded under current-clamp conditions. \*,  $p < 0.05$  versus control (paired Student's  $t$  test).


observed, which presumably reflects the mature (glycosylated) form of the channel expressed in the membrane (Li et al., 2000). However, p62-deficient mice showed a weak PKC $\zeta$ -K $_V$ 1.5 coimmunoprecipitation (Fig. 6B).

## Discussion

By using nonselective PKC inhibitors and the PKC $\zeta$ -selective inhibitor PKC $\zeta$ -PI, we suggested that PKC $\zeta$  was involved in the K $_V$  channel inhibition and the contractile response induced by TXA $_2$  in rat pulmonary artery myocytes (Cogolludo et al., 2003, 2005). Herein, we confirmed the role of PKC $\zeta$  in native K $_V$  currents by using PSMCs from PKC $\zeta^{-/-}$  mice. Consistent with the essential role of K $_V$ 1.5 channels in the pulmonary vasculature, we show that the K $_V$ 1.5 inhibitor DPO-1 inhibited K $_V$  currents in native rat PSMCs by approx. 50% and that the TXA $_2$  analog U46619 had no further

inhibitory effects. In addition, cloned human K $_V$ 1.5 channels expressed in Ltk $^-$  cells were also inhibited by U46619. Moreover, our results demonstrate the interaction between PKC $\zeta$  and K $_V$ 1.5 in both rat PAs and mouse lungs, which was minimal in p62 $^{-/-}$  mice. Deletion of p62 abolished K $_V$  channel inhibition and Ca $^{2+}$  responses induced by TXA $_2$ , further supporting the role of p62 as a key mediator between PKC $\zeta$  and K $_V$ 1.5. However, our study also showed that the contractile response induced by U46619 in PA was similar in wild-type and p62 $^{-/-}$  mice.

In both rat and newborn porcine PSMCs, U46619 inhibited K $_V$  currents, depolarized cell membrane, increased [Ca $^{2+}$ ] $_i$  through Ca $_L$  channels, and induced a contractile response (Cogolludo et al., 2003, 2005). U46619 had no direct effect on Ca $_L$  channels in voltage-clamped cells, indicating that increased Ca $^{2+}$  entry through Ca $_L$  channels is secondary




**Fig. 4.** PAs from p62 $^{-/-}$  mice show no [Ca $^{2+}$ ] $_i$  responses but preserved contractions induced by TP receptor activation. A and B, simultaneous recordings of [Ca $^{2+}$ ] $_i$  (top trace) and force (bottom trace) in PA from p62 $^{+/+}$  and p62 $^{-/-}$ , respectively, stimulated by 30 and 300 nM U46619. The averaged values (means  $\pm$  S.E.M. of five PAs) of U46619-induced increase in [Ca $^{2+}$ ] $_i$  and force are shown in C and D, respectively. \*,  $p < 0.05$  versus p62 $^{+/+}$  (unpaired Student's  $t$  test).

to membrane depolarization. Herein, we demonstrated that, in mice, U46619 also inhibits K $_V$  currents in PASMCs and induces a [Ca $^{2+}$ ] $_i$  response and vasoconstriction in isolated PA. The degree of K $_V$  channel inhibition in mice PASMCs (~25% at 100 nM U46619) was similar to that observed in porcine and in rat PA, and it was accompanied by a significant membrane depolarization. In rat and porcine PAs, all these effects were inhibited by calphostin C and PKC $\zeta$ -PI (Cogolludo et al., 2003, 2005). These experiments suggested a role for PKC $\zeta$  as a link between TP receptors and K $_V$  channels, which was confirmed in the present study using PKC $\zeta^{-/-}$  mice. The magnitude and current-voltage relationship of K $_V$  currents were similar in the wild-type and knockout animals, suggesting no changes in the channel proteins underlying K $_V$  currents. Thus, genetic inactivation or pharmacological inhibition of PKC $\zeta$  abolished the effects of U46619 on K $_V$  currents or membrane potential in PASMCs.

In contrast, both approaches only partially inhibited (~50–70%) the Ca $^{2+}$  signal induced by U46619 in rat and mice PAs, indicating that, in addition to the PKC $\zeta$ -K $_V$ -Ca $_L$  pathway, mechanisms increasing [Ca $^{2+}$ ] $_i$  (e.g., Ca $^{2+}$  release from intracellular stores) are also activated in response to U46619 (Snetkov et al., 2006).

The present experiments also indicate that in mice, PKC $\zeta$  contributes to the vasoconstriction induced by TP receptor activation. These results are in agreement with those obtained in rats and newborn piglets using PKC $\zeta$ -PI (Cogolludo et al., 2003, 2005). However, in 2-week-old piglets (Cogolludo et al., 2005), PKC $\zeta$ -PI and the Ca $^{2+}$  channel blocker nifedipine almost fully inhibited U46619-induced increases in [Ca $^{2+}$ ] $_i$ , but they had no effect on U46619-induced contractile responses; i.e., there was a contractile response in the absence of changes in [Ca $^{2+}$ ] $_i$ . Therefore, in these animals, the up-regulation of Ca $^{2+}$ -independent mechanisms for contrac-



**Fig. 5.** Role of K $_V$ 1.5 channels: TP receptor activation inhibits K $_V$ 1.5 currents and increases coimmunoprecipitation of K $_V$ 1.5 with PKC $\zeta$ . **A**, current traces recorded in Ltk $^{-}$  cells stably transfected with human K $_V$ 1.5 before (control) and after 100 nM U46619 and current-voltage relationship (means  $\pm$  S.E.M. of four cells) measured at the end of the 200-ms pulse. Depolarizing steps from -60 to +60 mV were applied from a holding potential of -60 mV. \*,  $p < 0.05$  versus control (paired Student's  $t$  test). **B**, current traces recorded in rat PASMCs cells before (control) and after the 100 nM U46619 (top) or before (control), after DPO-1 (300 nM), and after DPO-1 plus U46619 (bottom). Current-voltage relationships are shown at the right (means  $\pm$  S.E.M. of three to four cells). \*,  $p < 0.05$  versus control (paired Student's  $t$  test). **C**, rat pulmonary arteries were incubated for 30 s in the absence (control) or presence of 100 nM U46619, frozen, and homogenated. Homogenates were immunoprecipitated with anti-K $_V$ 1.5 antibodies and immunoblotted with anti-PKC $\zeta$  or anti-p62. Results are representative of samples from seven to eight mice. Each pair of bands (control and U46619) is obtained from the same animal.

tion (Somlyo and Somlyo, 2000) makes PKC $\zeta$  and the  $[Ca^{2+}]_i$  signal redundant.

K $_V$  currents recorded in native PASMCs reflect the contribution of multiple K $_V$  channel proteins [e.g., in human PAs, 22 transcripts of K $_V\alpha$  subunits: K $_V$ 1.1 to K $_V$ 1.7, K $_V$ 1.10, K $_V$ 2.1, K $_V$ 3.1, K $_V$ 3.3, K $_V$ 3.4, K $_V$ 4.1, K $_V$ 4.2, K $_V$ 5.1, K $_V$ 6.1 to -6.3, K $_V$ 9.1, K $_V$ 9.3, K $_V$ 10.1, and K $_V$ 11.1, and three of K $_V\beta$  subunits K $_V\beta$ 1 to -3 have been identified by reverse transcription-polymerase chain reaction]. However, K $_V$ 1.5 subunits are thought to be major contributors of the native K $_V$  currents in PAs from different species, and their activity is regulated by vasoactive factors such as 5-hydroxytryptamine (Cogolludo et al., 2006) and hypoxia (Platoshyn et al., 2006). Therefore, we analyzed the effects of U46619 on the K $_V$  current carried by human cloned K $_V$ 1.5 channels expressed in mouse fibroblast (Ltk $^-$ ) cells. This cell line expresses endogenously the K $_V\beta$ 2.1 subunit, which assembles with the transfected hK $_V$ 1.5 protein (Uebele et al., 1996). U46619 induced a weak but significant inhibitory effect on this current, suggesting that K $_V$ 1.5 channels are involved in the effects of TP receptor activation in native PASMCs. The small inhibition in this cell type probably reflects a lower efficacy of the signaling pathway compared with rat or mouse PASMCs. Furthermore, after pharmacological inhibition of


K $_V$ 1.5 channels with DPO-1, U46619 had no further inhibitory effects on K $_V$  currents in rat PASMCs.

In the present article, we show that PKC $\zeta$  coimmunoprecipitates with K $_V$ 1.5 channels. In a previous study (Cogolludo et al., 2003), we reported that U46619 induced the translocation of PKC $\zeta$  from the cytosolic to the membrane fraction. Therefore, TP receptor-induced K $_V$  channel inhibition is associated with the translocation of PKC $\zeta$  to the plasma membrane where it interacts with K $_V$ 1.5 channels. This PKC $\zeta$ -K $_V$ 1.5 interaction is not necessarily a direct protein-protein interaction; it seems more likely that it is mediated by adaptor proteins. In this regard, it has been described that PKC $\zeta$  can interact with the  $\beta$  subunit K $_V\beta$ 2 of the K $_V$  channel via the p62 adaptor protein (Gong et al., 1999). In immunoprecipitation experiments, we found that p62 was present in the K $_V$ 1.5-PKC $\zeta$  complex. Even when the complex was constitutive, the association of p62 with K $_V$ 1.5 increased significantly by U46619. Furthermore, the PKC $\zeta$ -K $_V$ 1.5 coimmunoprecipitation was strongly reduced in p62 $^{-/-}$  mouse lung, indicating that p62 physically associates PKC $\zeta$  into the K $_V$  channel complex.

K $_V\beta$  subunits function as molecular chaperones, and they can directly regulate channel inactivation, voltage dependence, and current amplitude (Martens et al., 1999). p62 overexpression stimulates PKC $\zeta$ -dependent phosphorylation of K $_V\beta$ 2 (Gong et al., 1999), and it induces a hyperpolarizing shift of K $_V$  current activation in pheochromocytoma cells (Kim et al., 2004). Thus, we analyzed the effect of genetic inactivation of p62 on K $_V$  currents and its modulation by TP receptor activation. K $_V$  currents in PASMCs from p62 $^{-/-}$  were similar to wild type. As expected, U46619 had no effect on K $_V$  currents in p62 $^{-/-}$  PASMCs, indicating that the p62-dependent PKC $\zeta$ -K $_V$ 1.5 interaction is required for the inhibitory effect of TP receptor activation on K $_V$  current.

Thus, genetic inactivation of p62 had a similar effect to genetic or pharmacological inactivation of PKC $\zeta$  regarding K $_V$  current modulation. We were surprised to find that p62 gene deletion fully inhibited the  $Ca^{2+}$  response induced by U46619 in isolated PAs compared with a 50 to 70% inhibition by PKC $\zeta$  inactivation. More intriguingly, the contractile response to U46619 was not affected in PA from p62 $^{-/-}$  mice. This contractile response in the absence of changes in  $[Ca^{2+}]_i$  must then be attributed to  $Ca^{2+}$ -independent mechanisms (i.e.,  $Ca^{2+}$  sensitization; Somlyo and Somlyo, 2000). This response to U46619 in p62 $^{-/-}$  mice PA is similar to that observed in 2-week-old piglet PAs after inhibition of PKC $\zeta$  (i.e., contraction without  $[Ca^{2+}]_i$  signal) (Cogolludo et al., 2005). In these animals, there is an up-regulation of Rho kinase (Bailly et al., 2004), a key enzyme in  $Ca^{2+}$ -sensitizing mechanisms. In addition, Rho kinase inhibitors were more effective inhibiting U46619 contractions in these piglets than in newborn piglets or adult rats (Cogolludo et al., 2005). Thus, we speculate that the chronic down-regulation of the PKC $\zeta$ -p62-K $_V$ -Ca $_L$ -dependent pathway, either at the level of K $_V$  channel activity (as occurs in older piglets) or p62 (p62 $^{-/-}$  mice), but not PKC $\zeta$  (PKC $\zeta$  $^{-/-}$  mice), is compensated by up-regulation of  $Ca^{2+}$  sensitization mechanisms.

In conclusion, PKC $\zeta$  modulates K $_V$  channel function, and it is involved in pulmonary vasoconstriction induced by TP receptor activation. The interaction between PKC $\zeta$  and K $_V$ 1.5 and the inhibitory effect of U46619 in cloned human K $_V$ 1.5 channels suggest that these specific channel subtypes are



**Fig. 6.** Similar expression of PKC $\zeta$  and K $_V$ 1.5 but reduced interaction between PKC $\zeta$  and K $_V$ 1.5 in p62 $^{-/-}$  versus p62 $^{+/+}$ . **A**, representative Western blots of lung homogenates using anti-K $_V$ 1.5 and anti-PKC $\zeta$  antibodies. **B**, lung homogenates were immunoprecipitated with anti-PKC $\zeta$  antibodies and immunoblotted with anti-K $_V$ 1.5; membranes were reblotted with the anti-PKC $\zeta$  antibody as a loading control. The graph shows the densitometric analysis of the K $_V$ 1.5 protein relative to PKC $\zeta$  and expressed as a percentage of values in wild-type mice. \*\*,  $p < 0.01$  versus wild type.



functional targets for PKC $\zeta$ . The adaptor protein p62 is required for the PKC $\zeta$ -K $_v$ 1.5 interaction and hence for the inhibition of K $_v$  currents after TP receptor activation.

## References

- Archer S, Souil E, Dinh-Xuan AT, Schremmer B, Mercier JC, El Yaagoubi A, Nguyen-Huu L, Reeve HL, and Hampl V (1998) Molecular identification of the role of voltage-gated K $^+$  channels, Kv1.5 and Kv1.2, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. *J Clin Invest* **101**:2319–2330.
- Bailly K, Ridley AJ, Hall SM, and Haworth SG (2004) RhoA activation by hypoxia in pulmonary arterial smooth muscle cells is age and site specific. *Circ Res* **94**:1383–1391.
- Barnes PJ and Liu SF (1995) Regulation of pulmonary vascular tone. *Pharmacol Rev* **47**:87–131.
- Cogolludo A, Moreno L, Bosca L, Tamargo J, and Perez-Vizcaino F (2003) Thromboxane A $_2$ -induced inhibition of voltage-gated K $^+$  channels and pulmonary vasoconstriction: role of protein kinase C $\zeta$ . *Circ Res* **93**:656–663.
- Cogolludo A, Moreno L, Lodi F, Frazziano G, Cobeno L, Tamargo J, and Perez-Vizcaino F (2006) Serotonin inhibits voltage-gated K $^+$  currents in pulmonary artery smooth muscle cells: role of 5-HT $_2$ A receptors, caveolin-1, and K $_v$ 1.5 channel internalization. *Circ Res* **98**:931–938.
- Cogolludo A, Moreno L, Lodi F, Tamargo J, and Perez-Vizcaino F (2005) Postnatal maturational shift from PKC $\zeta$  and voltage-gated K $^+$  channels to RhoA/Rho kinase in pulmonary vasoconstriction. *Cardiovasc Res* **66**:84–93.
- Durán A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J, and Diaz-Meco MT (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. *Dev Cell* **6**:303–309.
- Frey RS, Gao X, Javaid K, Siddiqui SS, Rahman A, and Malik AB (2006) Phosphatidylinositol 3-kinase  $\gamma$  signaling through protein kinase C $\zeta$  induces NADPH oxidase-mediated oxidant generation and NF- $\kappa$ B activation in endothelial cells. *J Biol Chem* **281**:16128–16138.
- Gayral S, Deleris P, Laulagnier K, Laffargue M, Salles JP, Perret B, Record M, and Breton-Douillon M (2006) Selective activation of nuclear phospholipase D-1 by g protein-coupled receptor agonists in vascular smooth muscle cells. *Circ Res* **99**:132–139.
- Godeny MD and Sayeski PP (2006) G II-induced cell proliferation is dually mediated by c-Src/Yes/Fyn-regulated ERK1/2 activation in the cytoplasm and PKC $\zeta$ -controlled ERK1/2 activity within the nucleus. *Am J Physiol Cell Physiol* **291**:C1297–C1307.
- Gong J, Xu J, Bezanilla M, van Huizen R, Derin R, and Li M (1999) Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2. *Science* **285**:1565–1569.
- Halushka PV, Mais DE, Mayeux PR, and Morinelli TA (1989) Thromboxane, prostaglandin and leukotriene receptors. *Annu Rev Pharmacol Toxicol* **29**:213–239.
- Hirai T and Chida K (2003) Protein kinase C  $\zeta$  (PKC $\zeta$ ): activation and cellular functions. *J Biochem* **133**:1–7.
- Kim Y, Park MK, Uhm DY, Shin J, and Chung S (2005) Modulation of delayed rectifier potassium channels by alpha1-adrenergic activation via protein kinase C zeta and p62 in PC12 cells. *Neurosci Lett* **387**:43–48.
- Kim Y, Uhm DY, Shin J, and Chung S (2004) Modulation of delayed rectifier potassium channel by protein kinase C zeta-containing signaling complex in pheochromocytoma cells. *Neuroscience* **125**:359–368.
- Krotova K, Hu H, Xia SL, Belayev L, Patel JM, Block ER, and Zharikov S (2006) Peptides modified by myristoylation activate eNOS in endothelial cells through Akt phosphorylation. *Br J Pharmacol* **148**:732–740.
- Lagrutta A, Wang J, Fermini B, and Salata JJ (2006) Novel, potent inhibitors of human Kv1.5 K $^+$  channels and ultrarapidly activating delayed rectifier potassium current. *J Pharmacol Exp Ther* **317**:1054–1063.
- Leitges M, Sanz L, Martin P, Duran A, Braun U, Garcia JF, Camacho F, Diaz-Meco MT, Rennert PD, and Moscat J (2001) Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. *Mol Cell* **8**:771–780.
- Li D, Takimoto K, and Levitan ES (2000) Surface expression of Kv1 channels is governed by a C-terminal motif. *J Biol Chem* **275**:11597–11602.
- Liu LZ, Zhao HL, Zuo J, Ho SK, Chan JC, Meng Y, Fang FD, and Tong PC (2006) Protein kinase Czeta mediates insulin-induced glucose transport through actin remodelling in L6 muscle cells. *Mol Biol Cell* **17**:2322–2330.
- Martens JR, Kwak Y-G, and Tamkun MM (1999) Modulation of Kv channel  $\alpha/\beta$  subunit interactions. *Trends Cardiovasc Med* **9**:253–258.
- Moscat J and Diaz-Meco MT (2000) The atypical protein kinase Cs. Functional specificity mediated by specific protein adaptors. *EMBO Rep* **1**:399–403.
- Pérez-Vizcaino F, Cogolludo A, and Tamargo J (1999) Modulation of arterial Na $^+$ -K $^+$ -ATPase-induced [Ca $^{2+}$ ] $_i$  reduction and relaxation by norepinephrine, ET-1, and PMA. *Am J Physiol* **276**:H651–H657.
- Platoshyn O, Brevnova EE, Burg ED, Yu Y, Remillard CV, and Yuan JX (2006) Acute hypoxia selectively inhibits KCNA5 channels in pulmonary artery smooth muscle cells. *Am J Physiol Cell Physiol* **290**:C907–C916.
- Pozeg ZI, Michelakis ED, McMurtry MS, Thebaud B, Wu XC, Dyck JR, Hashimoto K, Wang S, Moudgil R, Harry G, et al. (2003) In vivo gene transfer of the O $_2$ -sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. *Circulation* **107**:2037–2044.
- Remillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D, Nicholson A, Rana BK, Channick RN, Rubin LJ, et al. (2007) Function of Kv1.5 channels and genetic variations in KCNA5 in patients with idiopathic pulmonary arterial hypertension. *Am J Physiol Cell Physiol* **292**:C1837–C1853.
- Salamanca DA and Khalil RA (2005) Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. *Biochem Pharmacol* **70**:1537–1547.
- Shimoda LA, Sylvestre JT, Booth GM, Shimoda TH, Meeker S, Udem BJ, and Sham JS (2001) Inhibition of voltage-gated K $^+$  currents by endothelin-1 in human pulmonary arterial myocytes. *Am J Physiol Lung Cell Mol Physiol* **281**:L1115–L1122.
- Shizukuda Y and Buttrick PM (2002) Protein kinase C-zeta modulates thromboxane A $_2$ -mediated apoptosis in adult ventricular myocytes via Akt. *Am J Physiol Heart Circ Physiol* **282**:H320–H327.
- Snetkov VA, Knock GA, Baxter L, Thomas GD, Ward JP, and Aaronson PI (2006) Mechanisms of the prostaglandin F $_{2\alpha}$ -induced rise in [Ca $^{2+}$ ] $_i$  in rat intrapulmonary arteries. *J Physiol* **571**:147–163.
- Somlyo AP and Somlyo AV (2000) Signal transduction by G-proteins, Rho kinase and protein phosphatase to smooth muscle and non-muscle myosin II. *J Physiol* **522**:177–185.
- Uebele VN, England SK, Chaudhary A, Tamkun MM, and Snyders DJ (1996) Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv $\beta$ 2.1 subunits. *J Biol Chem* **271**:2406–2412.
- Valenzuela C, Delpon E, Tamkun MM, Tamargo J, and Snyders DJ (1995) Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. *Biophys J* **69**:418–427.
- Ward JP, Knock GA, Snetkov VA, and Aaronson PI (2004) Protein kinases in vascular smooth muscle tone—role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. *Pharmacol Ther* **104**:207–231.
- Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, and Archer SL (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. *Circulation* **94**:2216–2220.
- Yuan XJ, Wang J, Juhaszova M, Gaine SP, and Rubin LJ (1998a) Attenuated K $^+$  channel gene transcription in primary pulmonary hypertension. *Lancet* **351**:726–727.
- Yuan X-J, Wang J, Juhaszova M, Golovina VA, and Rubin LJ (1998b) Molecular basis and function of voltage-gated K $^+$  channels in pulmonary arterial smooth muscle. *Am J Physiol* **274**:L621–L635.

**Address correspondence to:** Dr. Francisco Perez-Vizcaino, Department of Pharmacology, School of Medicine, Universidad Complutense, 28040 Madrid, Spain. E-mail: fperez@med.ucm.es